Cargando…
Interleukin-1 mediates Alzheimer and Lewy body pathologies
BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid pla...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435743/ https://www.ncbi.nlm.nih.gov/pubmed/16542445 http://dx.doi.org/10.1186/1742-2094-3-5 |
_version_ | 1782127268386045952 |
---|---|
author | Griffin, W Sue T Liu, Ling Li, Yuekui Mrak, Robert E Barger, Steven W |
author_facet | Griffin, W Sue T Liu, Ling Li, Yuekui Mrak, Robert E Barger, Steven W |
author_sort | Griffin, W Sue T |
collection | PubMed |
description | BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid plaques, and neurofibrillary tangles (hyperphosphorylated tau aggregates). The co-occurrence of these clinical and neuropathological changes suggests shared pathogenic mechanisms in these diseases, previously assumed to be distinct. Glial activation, with overexpression of interleukin-1 (IL-1) and other proinflammatory cytokines, has been increasingly implicated in the pathogenesis of both AD and PD. METHODS: Rat primary cultures of microglia and cortical neurons were cultured either separately or as mixed cultures. Microglia or cocultures were treated with a secreted fragment (sAPPα) of the β-amyloid precursor protein (βAPP). Neurons were treated with IL-1β or conditioned medium from sAPPα-activated microglia, with or without IL-1 receptor antagonist. Slow-release pellets containing either IL-1β or bovine serum albumin (control) were implanted in cortex of rats, and mRNA for various neuropathological markers was analyzed by RT-PCR. Many of the same markers were assessed in tissue sections from human cases of AD/LBD. RESULTS: Activation of microglia with sAPPα resulted in a dose-dependent increase in secreted IL-1β. Cortical neurons treated with IL-1β showed a dose-dependent increase in sAPPα release, an effect that was enhanced in the presence of microglia. IL-1β also elevated the levels of α-synuclein, activated MAPK-p38, and phosphorylated tau; a concomitant decrease in levels of synaptophysin occurred. Delivery of IL-1β by slow-release pellets elevated mRNAs encoding α-synuclein, βAPP, tau, and MAPK-p38 compared to controls. Finally, human cases of AD/LBD showed colocalization of IL-1-expressing microglia with neurons that simultaneously overexpressed βAPP and contained both Lewy bodies and neurofibrillary tangles. CONCLUSION: Our findings suggest that IL-1 drives production of substrates necessary for formation of the major neuropathological changes characteristic of AD/LBD. |
format | Text |
id | pubmed-1435743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-14357432006-04-13 Interleukin-1 mediates Alzheimer and Lewy body pathologies Griffin, W Sue T Liu, Ling Li, Yuekui Mrak, Robert E Barger, Steven W J Neuroinflammation Research BACKGROUND: Clinical and neuropathological overlap between Alzheimer's (AD) and Parkinson's disease (PD) is now well recognized. Such cases of concurrent AD and Lewy body disease (AD/LBD) show neuropathological changes that include Lewy bodies (α-synuclein aggregates), neuritic amyloid plaques, and neurofibrillary tangles (hyperphosphorylated tau aggregates). The co-occurrence of these clinical and neuropathological changes suggests shared pathogenic mechanisms in these diseases, previously assumed to be distinct. Glial activation, with overexpression of interleukin-1 (IL-1) and other proinflammatory cytokines, has been increasingly implicated in the pathogenesis of both AD and PD. METHODS: Rat primary cultures of microglia and cortical neurons were cultured either separately or as mixed cultures. Microglia or cocultures were treated with a secreted fragment (sAPPα) of the β-amyloid precursor protein (βAPP). Neurons were treated with IL-1β or conditioned medium from sAPPα-activated microglia, with or without IL-1 receptor antagonist. Slow-release pellets containing either IL-1β or bovine serum albumin (control) were implanted in cortex of rats, and mRNA for various neuropathological markers was analyzed by RT-PCR. Many of the same markers were assessed in tissue sections from human cases of AD/LBD. RESULTS: Activation of microglia with sAPPα resulted in a dose-dependent increase in secreted IL-1β. Cortical neurons treated with IL-1β showed a dose-dependent increase in sAPPα release, an effect that was enhanced in the presence of microglia. IL-1β also elevated the levels of α-synuclein, activated MAPK-p38, and phosphorylated tau; a concomitant decrease in levels of synaptophysin occurred. Delivery of IL-1β by slow-release pellets elevated mRNAs encoding α-synuclein, βAPP, tau, and MAPK-p38 compared to controls. Finally, human cases of AD/LBD showed colocalization of IL-1-expressing microglia with neurons that simultaneously overexpressed βAPP and contained both Lewy bodies and neurofibrillary tangles. CONCLUSION: Our findings suggest that IL-1 drives production of substrates necessary for formation of the major neuropathological changes characteristic of AD/LBD. BioMed Central 2006-03-16 /pmc/articles/PMC1435743/ /pubmed/16542445 http://dx.doi.org/10.1186/1742-2094-3-5 Text en Copyright © 2006 Griffin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Griffin, W Sue T Liu, Ling Li, Yuekui Mrak, Robert E Barger, Steven W Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title | Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title_full | Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title_fullStr | Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title_full_unstemmed | Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title_short | Interleukin-1 mediates Alzheimer and Lewy body pathologies |
title_sort | interleukin-1 mediates alzheimer and lewy body pathologies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435743/ https://www.ncbi.nlm.nih.gov/pubmed/16542445 http://dx.doi.org/10.1186/1742-2094-3-5 |
work_keys_str_mv | AT griffinwsuet interleukin1mediatesalzheimerandlewybodypathologies AT liuling interleukin1mediatesalzheimerandlewybodypathologies AT liyuekui interleukin1mediatesalzheimerandlewybodypathologies AT mrakroberte interleukin1mediatesalzheimerandlewybodypathologies AT bargerstevenw interleukin1mediatesalzheimerandlewybodypathologies |